{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T18:03:56Z","timestamp":1790705036772,"version":"4.1.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T00:00:00Z","timestamp":1771286400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalmicrobiologyandinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.cmi.2026.02.005","type":"journal-article","created":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T08:02:12Z","timestamp":1770883332000},"page":"951-958","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Tumour necrosis factor-\u03b1 inhibitors, immune-mediated inflammatory diseases, and bloodstream infections: results from a nationwide case-control study"],"prefix":"10.1016","volume":"32","author":[{"given":"C\u00e6cilie","family":"Leding","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Meddis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon Gitz","family":"Holler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Burisch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tue Wenzel","family":"Kragstrup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lone","family":"Skov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Benfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cmi.2026.02.005_bib1","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1124\/jpet.301.2.418","article-title":"Binding and functional comparisons of two types of tumor necrosis factor antagonists","volume":"301","author":"Scallon","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.cmi.2026.02.005_bib2","series-title":"Medicines European Medicines Agency (EMA)","year":"2023"},{"key":"10.1016\/j.cmi.2026.02.005_bib3","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/ard-2022-223356","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update","volume":"82","author":"Smolen","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.cmi.2026.02.005_bib4","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1093\/ecco-jcc\/jjae091","article-title":"ECCO Guidelines on therapeutics in Crohn\u2019s disease: medical treatment","volume":"18","author":"Gordon","year":"2024","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.cmi.2026.02.005_bib5","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1093\/ecco-jcc\/jjab178","article-title":"ECCO guidelines on therapeutics in ulcerative colitis: medical treatment","volume":"16","author":"Raine","year":"2022","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.cmi.2026.02.005_bib6","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1111\/jdv.16915","article-title":"EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris\u2014Part 1: treatment and monitoring recommendations","volume":"34","author":"Nast","year":"2020","journal-title":"J Eur Acad Dermatol Venereol JEADV"},{"key":"10.1016\/j.cmi.2026.02.005_bib7","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.cgh.2019.02.044","article-title":"Comparative risk of serious infections with biologic and\/or immunosuppressive therapy in patients with inflammatory bowel diseases: a systematic review and meta-analysis","volume":"18","author":"Singh","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cmi.2026.02.005_bib8","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jbspin.2016.02.028","article-title":"Safety of biologic DMARDs in RA patients in real life: a systematic literature review and meta-analyses of biologic registers","volume":"84","author":"de La Forest Divonne","year":"2017","journal-title":"Jt Bone Spine"},{"key":"10.1016\/j.cmi.2026.02.005_bib9","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1016\/j.cmi.2017.12.025","article-title":"ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [I]: anti-tumor necrosis factor-\u03b1 agents)","volume":"24","author":"Baddley","year":"2018","journal-title":"Clin Microbiol Infect Off"},{"key":"10.1016\/j.cmi.2026.02.005_bib10","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2024.1502893","article-title":"The increasing incidence and mortality of bacteremia in Denmark from 2010 to 2022: a population-based nationwide cohort study","volume":"12","author":"Dessau","year":"2024","journal-title":"Front Public Health"},{"key":"10.1016\/j.cmi.2026.02.005_bib11","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1016\/j.cmi.2018.03.030","article-title":"Contaminants in blood cultures: importance, implications, interpretation and prevention","volume":"24","author":"Darg\u00e8re","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2026.02.005_bib12","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1093\/aje\/kwaa167","article-title":"Do case-control studies always estimate odds ratios?","volume":"190","author":"Labrecque","year":"2021","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.cmi.2026.02.005_bib13","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1093\/rheumatology\/keq242","volume":"50","author":"Galloway","year":"2011","journal-title":"Rheumatol Oxf Engl"},{"key":"10.1016\/j.cmi.2026.02.005_bib14","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1001\/jamadermatol.2015.0718","article-title":"Risk of serious infection with biologic and systemic treatment of psoriasis: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR)","volume":"151","author":"Kalb","year":"2015","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.cmi.2026.02.005_bib15","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1053\/j.gastro.2018.04.012","article-title":"Risk of serious and opportunistic infections associated with treatment of inflammatory bowel diseases","volume":"155","author":"Kirchgesner","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cmi.2026.02.005_bib16","first-page":"680","article-title":"Five-year safety data from ENCORE, a European observational safety registry for adults with Crohn\u2019s disease treated with infliximab (Remicade\u00ae) or conventional therapy","volume":"11","author":"D\u2019Haens","year":"2017","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.cmi.2026.02.005_bib17","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2022-002636","article-title":"Antirheumatic treatment, disease activity and risk of Staphylococcus aureus bacteraemia in rheumatoid arthritis: a nationwide nested case\u2013control study","volume":"8","author":"Dieperink","year":"2022","journal-title":"RMD Open"},{"key":"10.1016\/j.cmi.2026.02.005_bib18","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1164\/rccm.200302-303OC","article-title":"Modulation of bacterial growth by tumor necrosis factor-alpha in vitro and in vivo","volume":"168","author":"Lee","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.cmi.2026.02.005_bib19","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1001\/jamadermatol.2021.2599","article-title":"Association between biologics use and risk of serious infection in patients with psoriasis","volume":"157","author":"Penso","year":"2021","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.cmi.2026.02.005_bib20","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-003865","article-title":"Risk of serious infection associated with different classes of targeted therapies used in psoriatic arthritis: a nationwide cohort study from the French Health Insurance Database (SNDS)","volume":"10","author":"Bastard","year":"2024","journal-title":"RMD Open"},{"key":"10.1016\/j.cmi.2026.02.005_bib21","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1093\/rheumatology\/kead515","article-title":"Evaluation of serious infections, including Mycobacterium tuberculosis, during treatment with biologic disease-modifying anti-rheumatic drugs: does line of therapy matter?","volume":"63","author":"Lauper","year":"2024","journal-title":"Rheumatol Oxf Engl"},{"key":"10.1016\/j.cmi.2026.02.005_bib22","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1136\/ard-2022-223762","article-title":"Safety of biological and targeted synthetic disease-modifying antirheumatic drugs for rheumatoid arthritis as used in clinical practice: results from the ARTIS programme","volume":"82","author":"Frisell","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.cmi.2026.02.005_bib23","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1002\/acr.22815","article-title":"Comparative risk of harm associated with the use of targeted immunomodulators: a systematic review","volume":"68","author":"Desai","year":"2016","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.cmi.2026.02.005_bib24","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1001\/jama.2011.1692","article-title":"Initiation of tumor necrosis factor-\u03b1 antagonists and the risk of hospitalization for infection in patients with autoimmune diseases","volume":"306","author":"Grijalva","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.cmi.2026.02.005_bib25","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1038\/ajg.2012.218","article-title":"Serious infection and mortality in patients with Crohn\u2019s disease: more than 5 years of follow-up in the TREATTM registry","volume":"107","author":"Lichtenstein","year":"2012","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cmi.2026.02.005_bib26","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1093\/cid\/ciae444","article-title":"Incidence and risk factors for invasive fungal infections in patients initiating tumor necrosis factor\u2013alpha inhibitors for inflammatory bowel disease and rheumatoid arthritis","volume":"80","author":"Hennessee","year":"2025","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2026.02.005_bib27","doi-asserted-by":"crossref","first-page":"870","DOI":"10.7326\/M20-1594","article-title":"Risk for serious infection with low-dose glucocorticoids in patients with rheumatoid arthritis","volume":"173","author":"George","year":"2020","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cmi.2026.02.005_bib28","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.mayocp.2016.04.023","article-title":"Use of glucocorticoids and risk of community-acquired Staphylococcus aureus bacteremia: a population-based case-control study","volume":"91","author":"Smit","year":"2016","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.cmi.2026.02.005_bib29","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1136\/ard.2011.151043","article-title":"Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient?","volume":"70","author":"Strangfeld","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.cmi.2026.02.005_bib30","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.h2809","article-title":"Association between tumour necrosis factor-\u03b1 inhibitors and risk of serious infections in people with inflammatory bowel disease: nationwide Danish cohort study","volume":"350","author":"Nyboe Andersen","year":"2015","journal-title":"BMJ"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X26000637?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X26000637?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T20:15:18Z","timestamp":1778962518000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X26000637"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S1198743X26000637"],"URL":"https:\/\/doi.org\/10.1016\/j.cmi.2026.02.005","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tumour necrosis factor-\u03b1 inhibitors, immune-mediated inflammatory diseases, and bloodstream infections: results from a nationwide case-control study","name":"articletitle","label":"Article Title"},{"value":"Clinical Microbiology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cmi.2026.02.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.cmi.2026.03.020","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases.","name":"copyright","label":"Copyright"}]}}